Streetbeat News

Revenues

IRMD

iRadimed (NASDAQ:IRMD) reported Q2 2024 adjusted EPS of $0.42, beating the $0.36 estimate by 16.67%. Sales were $17.929M, surpassing the $17.649M estimate and marking an 11.15% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:37 pm

IDCC

InterDigital (NASDAQ:IDCC) reported Q2 adjusted EPS of $4.57, a 251.54% increase YoY, and sales of $223.49M, a 119.99% increase YoY, beating analyst estimates by 124.21%.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:36 pm

ARM

AZN

EWU

FXB

HSBC

RIO

SHEL

UL

The Bank of England (BoE) reduced its key interest rate by 25 basis points to 5%, marking the first cut in over four years. The decision was divided among the Monetary Policy Committee members. The BoE expects inflation to rise to 2.75% later this year but fall below target in the next two years. The British pound fell 0.5% against the dollar, while UK equities remained flat. US-listed British companies showed mixed premarket performances.

Portfolio Pulse from Piero Cingari

August 01, 2024 | 12:35 pm

HSY

The Hershey Company (NYSE:HSY) reported disappointing Q2 earnings and sales, missing analyst expectations due to a challenging consumer environment. Adjusted EPS fell 36.8% to $1.27, and sales dropped 16.7% to $2.07 billion. The company cited higher commodity costs and lower retailer inventory as key issues. Despite these challenges, Hershey announced quarterly dividends and adjusted its full-year outlook downward.

Portfolio Pulse from Nabaparna Bhattacharya

August 01, 2024 | 12:35 pm

ITRI

Itron has updated its Q3 and FY24 guidance, projecting higher EPS and revenue than previously estimated. For Q3, EPS is expected to be $1.10-$1.20 vs. $0.92 estimated, and revenue is projected at $590M-$600M vs. $586.09M estimated. For FY24, EPS guidance is raised to $4.45-$4.65 vs. $4.07 estimated, and revenue is increased to $2.385B-$2.415B vs. $2.38B estimated.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:33 pm

AMD

LRCX

Lam Research Corporation (NASDAQ:LRCX) experienced a 2.63% dip in pre-market trading despite strong quarterly earnings and projections. The company reported revenue of $3.87 million and a non-GAAP gross margin of 48.5% for the June 2024 quarter. Despite surpassing analyst revenue predictions for the next quarter, the stock dipped, likely due to high investor expectations. Increased demand for AI-powered chips benefits Lam Research, which competes with Applied Materials, ASML, and KLA Corp.

Portfolio Pulse from Benzinga Neuro

August 01, 2024 | 12:33 pm

GH

Guardant Health has announced FDA approval and Medicare coverage for its Shield blood test, which is now commercially available as the first FDA-approved blood test for primary colorectal cancer screening.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:33 pm

ITRI

Itron (NASDAQ:ITRI) reported strong Q2 earnings, with adjusted EPS of $1.21 beating the $0.96 estimate and sales of $609.07M surpassing the $599.10M estimate. This represents significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:31 pm

PNW

Pinnacle West Capital (NYSE:PNW) reported Q2 2024 GAAP EPS of $1.76, beating the estimate of $1.34 by 31.34%. Sales were $1.309 billion, surpassing the $1.208 billion estimate and showing a 16.67% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:31 pm

SPY

The USA's continuing jobless claims have risen to 1,877K, surpassing the estimated 1,860K and the prior revised figure of 1,844K.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:30 pm